Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas

US7928239B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Jacques Dumas · Neuilly-Plaisance, FR
• Bernd Riedl · Wuppertal, DE
• Uday Khire · Hamden, US
• Jill Wood · Hampton, US
• Robert Sibley · North Haven, US
• Mary-Katherine Monahan · Hamden, US
• Joel Renick · San Diego, US
• David Gunn · Waukegan, US
• Timothy B. Lowinger · Carlisle, US
• William Scott · Guilford, US
• Roger Smith · Madison, US

Key dates

• Filing date: Feb 7, 2001
• Grant date: Apr 19, 2011
• Expiry date: Feb 7, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.